Market Movers | Winners: IVVD, PRTH, GRAL | Losers: EMAT, INDP, PBLS
A day of fresh moves at the market’s extremes raises questions about which new names have staying power.
Invivyd (IVVD) gained +35.0% today, while the day’s largest decline was a -14.7% move for Evolution Metals & Technologies (EMAT). The moves came on a strong day for the major indices, with the S&P 500 up +1.5% and the Nasdaq-100 adding +2.8%.
With such large single-day moves, the immediate question is whether these are new trends or the continuation of old ones. The day’s biggest winners and losers tell the story.
Monday’s Market Winners
The 10 US-listed stocks in the Trefis coverage universe with the highest returns on the last trading day:
| # | Ticker | Company Name | 1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | IVVD | Invivyd | 35.0% | -58.7% |
| 2 | PRTH | Priority Technology | 33.8% | 43.1% |
| 3 | GRAL | GRAIL | 33.7% | 26.1% |
| 4 | NUAI | New Era Energy & Digital | 30.5% | 161.1% |
| 5 | NXTT | Next Technology | 26.1% | 12.1% |
| 6 | VGZ | Vista Gold | 21.2% | 39.1% |
| 7 | OPTX | Syntec Optics | 16.2% | 175.9% |
| 8 | GRPN | Groupon | 15.6% | 25.2% |
| 9 | FSLY | Fastly | 14.9% | 169.4% |
| 10 | YSS | York Space Systems | 14.2% | n/a |
Monday’s Market Losers
And the 10 US-listed stocks in the Trefis coverage universe with the lowest returns:
| # | Ticker | Company Name | 1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | EMAT | Evolution Metals & Technologies | -14.7% | n/a |
| 2 | INDP | Indaptus Therapeutics | -13.0% | 6.2% |
| 3 | PBLS | Parabilis Medicines | -11.5% | n/a |
| 4 | TPB | Turning Point Brands | -10.0% | -43.3% |
| 5 | ARTV | Artiva Biotherapeutics | -9.1% | 82.5% |
| 6 | ARCT | Arcturus Therapeutics | -8.4% | 139.6% |
| 7 | ABX | Abacus Global Management | -8.2% | -5.8% |
| 8 | CXW | CoreCivic | -8.0% | 69.6% |
| 9 | ITG | ITG | -7.8% | n/a |
| 10 | GMRS | GMR Solutions | -7.8% | n/a |
The day’s extremes are mostly fresh moves.
No stock appears on both the one-day and one-month leaderboards on the same side today, so the day’s extremes are mostly fresh moves rather than continuations. The day’s top gainer, Invivyd (IVVD), has a market value of about $326.8 million and saw its revenue grow 26.3% over the last twelve months. In contrast, the day’s largest decliner, Evolution Metals & Technologies (EMAT), has a market value of about $2.1 billion.
Movers Over The Last Week
Widening the window to five trading days, these are the strongest and weakest names in the Trefis coverage universe:
Winners
| # | Ticker | Company Name | 1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | SDGR | Schrodinger | 45.7% | 69.1% |
| 2 | GRAL | GRAIL | 42.9% | 26.1% |
| 3 | AXTI | AXT | 40.1% | 388.9% |
| 4 | LVWR | LiveWire | 39.1% | -65.4% |
| 5 | NUAI | New Era Energy & Digital | 36.6% | 161.1% |
| 6 | MXL | MaxLinear | 32.7% | 393.3% |
| 7 | ALAB | Astera Labs | 32.6% | 104.8% |
| 8 | CYPH | Cypherpunk Technologies | 31.8% | 193.1% |
| 9 | BBNX | Beta Bionics | 31.7% | -27.7% |
| 10 | PRTH | Priority Technology | 29.9% | 43.1% |
Losers
| # | Ticker | Company Name | 1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | ALHC | Alignment Healthcare | -35.6% | -57.8% |
| 2 | XENE | Xenon Pharmaceuticals | -33.0% | -13.0% |
| 3 | SWMR | Swarmer | -27.1% | n/a |
| 4 | ENVA | Enova International | -24.4% | 9.0% |
| 5 | ARTV | Artiva Biotherapeutics | -22.8% | 82.5% |
| 6 | FLNC | Fluence Energy | -21.5% | -62.6% |
| 7 | DMRA | Damora Therapeutics | -19.5% | -0.7% |
| 8 | AN | AutoNation | -17.9% | -18.3% |
| 9 | RSI | Rush Street Interactive | -17.7% | 11.0% |
| 10 | PALI | Palisade Bio | -17.6% | -28.1% |
Movers Over The Last Month
And over the last 21 trading days, the strongest and weakest names in the Trefis coverage universe:
Winners
| # | Ticker | Company Name | 1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | CYPH | Cypherpunk Technologies | 185.7% | 193.1% |
| 2 | INDP | Indaptus Therapeutics | 123.9% | 6.2% |
| 3 | BRR | ProCap Financial | 81.7% | 15.3% |
| 4 | FWDI | Forward Industries | 62.7% | 23.6% |
| 5 | TTRX | Turn Therapeutics | 60.8% | 289.3% |
| 6 | SDGR | Schrodinger | 54.4% | 69.1% |
| 7 | MSTR | Strategy | 49.9% | 10.9% |
| 8 | CVI | CVR Energy | 48.3% | 110.2% |
| 9 | GEMI | Gemini Space Station | 44.7% | -39.6% |
| 10 | OKTA | OKTA | 42.6% | 121.3% |
Losers
| # | Ticker | Company Name | 1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | ALMS | Alumis | -65.4% | -19.1% |
| 2 | SWMR | Swarmer | -48.9% | n/a |
| 3 | RARE | Ultragenyx Pharmaceutical | -42.1% | -36.3% |
| 4 | TTAN | ServiceTitan | -38.9% | -46.9% |
| 5 | FBYD | Falcons Beyond Global | -36.2% | -54.8% |
| 6 | ALHC | Alignment Healthcare | -35.6% | -57.8% |
| 7 | KRMN | Karman | -35.2% | -51.9% |
| 8 | FLNC | Fluence Energy | -35.1% | -62.6% |
| 9 | XENE | Xenon Pharmaceuticals | -34.7% | -13.0% |
| 10 | DYN | Dyne Therapeutics | -34.1% | -12.5% |
What does a disciplined investor do with this list?
The tables earlier in this report show the largest percentage moves, which is a measure of volatility and market attention. They are not a set of instructions. A large gain or loss is simply a signal that something has changed, prompting a closer look.
The disciplined next step is always the same. It is to investigate the underlying business behind any name that appears on these lists, whether over one day or one month. The move itself is just the beginning of the work.
The next step is never to trade the list; it is to test it. Our Guidance Momentum screen shows which risers have management raising guidance behind them, and our Buy the Dip screen shows which of the fallers still generate the growth and cash that make a recovery plausible.
Today’s Winner Is Tomorrow’s Loser Often Enough
The movers list is the most honest picture of single-stock risk the market prints each day: the same volatility that makes the winners column also fills the losers column, and no one reliably knows which side a stock lands on next.
That is the case for owning a disciplined basket instead of chasing the tape. The Trefis High Quality (HQ) Portfolio holds roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Watch the movers for information; let the portfolio do the compounding.